Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Ipamorelin
GH Increase2-3x
Studies8
Participants1,286
StatusAvailable

Ipamorelin

Selective Growth Hormone Secretagogue (GHRP)

Ipamorelin is a selective growth hormone releasing peptide (GHRP) that specifically stimulates the release of growth hormone without affecting other hormones. Unlike other GHRPs, Ipamorelin does not increase cortisol, acetylcholine, prolactin, or aldosterone levels, making it the most selective and well-tolerated growth hormone secretagogue available for research and therapeutic applications.

Clinical Benefits

Selective growth hormone secretagogue receptor activation
Increased natural growth hormone production
Enhanced IGF-1 levels and anabolic signaling
Improved lean muscle mass development
Enhanced fat loss and body composition
Better sleep quality and recovery

Mechanism of Action

Ipamorelin acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a) located in the anterior pituitary gland. Upon binding, it stimulates the release of growth hormone through a G-protein coupled receptor mechanism, specifically activating the GHS-R1a subtype. Unlike other growth hormone releasing peptides, Ipamorelin demonstrates remarkable selectivity, stimulating GH release without affecting the secretion of ACTH, cortisol, prolactin, FSH, LH, or TSH. This selective action is attributed to its specific receptor binding profile and downstream signaling cascade.

Key Action:

Proven Results

2.4%
Maximum Weight Loss
Clinical research data
0%
Diabetes Risk Reduction
Clinical research data
1,286
Total Participants
Research studies
0%
CV Risk Reduction
Clinical data

Medical Disclaimer

Ipamorelin is currently in research phase and is not FDA-approved for human therapeutic use. This information is for educational purposes only and should not replace consultation with healthcare providers. Individual results may vary. Medical supervision is recommended for all research applications.